Aspira Women's Health マネジメント

マネジメント基準チェック /04

Aspira Women's Healthの CEO はNicole Sandfordで、 Mar2022年に任命され、の在任期間は 2.67年です。の年間総報酬は$ 1.04Mで、 48.3%給与と51.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.52%を直接所有しており、その価値は€ 66.65K 。経営陣と取締役会の平均在任期間はそれぞれ0.9年と1.5年です。

主要情報

Nicole Sandford

最高経営責任者

US$1.0m

報酬総額

CEO給与比率	48.3%
CEO在任期間	2.7yrs
CEOの所有権	0.5%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	1.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Aspira Women's Health の収益と比較して、Nicole Sandford の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$16m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$1m	US$500k	-US$17m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$588k	US$417k	-US$30m
Sep 30 2022	n/a	n/a	-US$34m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$35m
Dec 31 2021	US$147k	n/a	-US$32m

報酬と市場: Nicoleの総報酬 ($USD 1.04M ) は、 German市場 ($USD 486.57K ) の同規模の企業の平均を上回っています。

報酬と収益: Nicoleの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Nicole Sandford (54 yo)

2.7yrs

在職期間

US$1,035,590

報酬

Ms. Nicole Sandford, C. P.A., serves as President & Chief Executive Officer of Aspira Women's Health Inc. since March 1, 2022 and serves as its Director since February 17, 2021 & serves as it's Interim CFO...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Nicole Sandford	CEO, Interim CFO & Director	2.7yrs	US$1.04m	0.52% € 66.7k
Sandra Milligan	President	less than a year	データなし	データなし
John Kallassy	Interim Chief Financial Officer	less than a year	データなし	データなし
Michelle Snider	Senior Vice President of Commercial Strategy & Operations	1.3yrs	データなし	データなし

0.9yrs

平均在職期間

経験豊富な経営陣: CULの経営陣は経験豊富とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Nicole Sandford	CEO, Interim CFO & Director	3.8yrs	US$1.04m	0.52% € 66.7k
Ellen Vos	Independent Director	1.5yrs	US$115.58k	0.36% € 46.2k
Daniel Chan	Member of Scientific Advisory Board	18.4yrs	データなし	データなし
Jannie Herchuk	Independent Chair of the Board	1.5yrs	US$118.83k	0.36% € 45.6k
Stefanie Cavanaugh	Independent Director	1.5yrs	US$113.96k	0.38% € 48.5k
Donald Munroe	Member of Scientific Advisory Board	no data	US$484.75k	データなし
Judith Wolf	Member of Scientific Advisory Board	no data	データなし	データなし
Robert Bristow	Member of Scientific Advisory Board	no data	データなし	データなし
Calaneet Balas	Member of Scientific Advisory Board	no data	データなし	データなし
Farr Nezhat	Member of Scientific Advisory Board	no data	データなし	データなし
Celeste Fralick	Independent Director	2.8yrs	US$178.00k	0.28% € 36.4k
Leo Twiggs	Chairman of Clinical Advisory Board	1.1yrs	データなし	データなし

1.5yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: CULの取締役会は経験豊富ではない ( 1.5年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Aspira Women's Health マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Aspira Women's Health Inc. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Aspira Women's Health Inc. to Report Nine Months, 2024 Results on Nov 14, 2024

Aspira Women's Health Inc. Announces Its Selection Receive $10 Million Award from Advanced Research Projects Agency for Health’s Sprint for Women's Health

Aspira Women's Health Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 2Q 2023)

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

New major risk - Shareholder dilution

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $4.45 million.

Aspira Women's Health Inc. to Report Q2, 2024 Results on Aug 12, 2024

Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors

New major risk - Shareholder dilution

Aspira Women's Health Inc. announced that it has received $1.910249 million in funding

Aspira Women’s Health Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Aspira Women's Health Inc. announced that it expects to receive $1.935051 million in funding

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2023)

Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024

Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: US$1.81 loss per share (vs US$3.85 loss in FY 2022)

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024

High number of new and inexperienced directors

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million.

Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors

Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023

Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Aspira Women's Health Establishes A New Clinical Advisory Board

Aspira Women’s Health Regains Nasdaq Compliance

Aspira Women’s Health Announces Executive Changes

Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023

Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023

Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors

Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023

First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022)

Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.28 loss in FY 2021)

Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Receives A Written Notice from Nasdaq

Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch

Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021)

Aspira Women's Health Inc. to Report Q3, 2022 Results on Nov 10, 2022

Aspira Women's Health Inc. Announces Publication of Its Second-Generation Multivariate Index Assay, Overa®, in the Detection of Cancer in Filipino Women

Aspira Women's Health Inc. has completed a Follow-on Equity Offering.

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.063 loss in 2Q 2021)

Aspira Women's Health Inc. to Report Q2, 2022 Results on Aug 10, 2022

Aspira Women's Health Inc. Announces Board Appointments

Aspira Women’s Health Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President recently bought €72k worth of stock

First quarter 2022 earnings released: US$0.083 loss per share (vs US$0.054 loss in 1Q 2021)

Aspira Women's Health Inc. Appoints Ryan Phan, Ph.D. as Chief Operating and Scientific Officer

Aspira Women's Health Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Aspira Women's Health Inc. Appoints Valerie B. Palmieri as Its Executive Chairperson

Aspira Women’S Health Announces Appointment of Celeste Fralick to Its Board of Directors

Aspira Women's Health Inc. Appoints Nicole Sandford as Chief Executive Officer, Effective March 1, 2022

Aspira Women’s Health, Inc. Name Mr. Michael Newton as Head of Sales and Marketing

Third quarter 2021 earnings released: US$0.087 loss per share (vs US$0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.063 loss per share (vs US$0.039 loss in 2Q 2020)

Aspira Women's Health Inc.(NasdaqCM:AWH) dropped from Russell 3000E Value Index

Independent Director David Schreiber has left the company

Aspira Women's Health Inc. Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health®

マネジメント基準チェック /04